Prostate cancer vaccines in combination with additional treatment modalities

被引：15
|
作者：
Uhlman, Matthew A. [1 ]
Bing, Megan T. [1 ]
Lubaroff, David M. [1 ,2 ,3 ]
机构：
[1] Univ Iowa, Dept Urol, Iowa City, IA 52242 USA
[2] Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA
[3] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA
来源：
IMMUNOLOGIC RESEARCH | 2014年 / 59卷 / 1-3期
关键词：
Prostate cancer; Immunotherapy; Cancer vaccines; Combination therapy; AUTOLOGOUS CELLULAR IMMUNOTHERAPY; SIPULEUCEL-T; IMMUNOSTIMULATORY PROPERTIES; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; RADIATION-THERAPY; ACID-PHOSPHATASE; DOUBLE-BLIND; PHASE-II; DOCETAXEL;
D O I：
10.1007/s12026-014-8532-1
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Immunotherapy has been investigated in both preclinical studies and clinical trials as a new therapy for prostate cancer. Vaccines, including those that utilize dendritic cells, viruses, or DNA, immunize against prostate-specific antigen and prostatic acid phosphatase. The vaccines have long been studied as monotherapy for the cancer, but increasingly more trials have been initiated in combination with other modalities. These include radiation, chemotherapy, and androgen deprivation therapy. This review describes and discusses the various combinations of vaccine immunotherapies.
引用
收藏
页码：236 / 242
页数：7
相关论文
共 50 条
  • [1] Prostate cancer vaccines in combination with additional treatment modalities
    Matthew A. Uhlman
    Megan T. Bing
    David M. Lubaroff
    Immunologic Research, 2014, 59 : 236 - 242
  • [2] Vaccines as Monotherapy and in Combination Therapy for Prostate Cancer
    Rotow, Julia
    Gameiro, Sofia R.
    Madan, Ravi A.
    Gulley, James L.
    Schlom, Jeffrey
    Hodge, James W.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2010, 3 (03): : 116 - 122
  • [3] Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Gamat-Huber, Melissa
    Jeon, Donghwan
    Johnson, Laura E.
    Moseman, Jena E.
    Muralidhar, Anusha
    Potluri, Hemanth K.
    Rastogi, Ichwaku
    Wargowski, Ellen
    Zahm, Christopher D.
    McNeel, Douglas G.
    CANCERS, 2020, 12 (10) : 1 - 23
  • [4] Prostate cancer vaccines
    Michael, Agnieszka
    Relph, Kate
    Annels, Nicola
    Pandha, Hardev
    EXPERT REVIEW OF VACCINES, 2013, 12 (03) : 253 - 262
  • [5] Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer
    Capuozzo, Maurizio
    Santorsola, Mariachiara
    Ianniello, Monica
    Ferrara, Francesco
    Zovi, Andrea
    Petrillo, Nadia
    Castiello, Rosa
    Fantuz, Maria Rosaria
    Ottaiano, Alessandro
    Savarese, Giovanni
    DISEASES, 2024, 12 (05)
  • [6] Systemic treatment for metastatic prostate cancer
    Gravis, Gwenaelle
    ASIAN JOURNAL OF UROLOGY, 2019, 6 (02) : 162 - 168
  • [7] Current Perspectives in Prostate Cancer Vaccines
    Arlen, Philip M.
    Gulley, James L.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (10) : 1052 - 1057
  • [8] Prostate cancer vaccines in clinical trials
    Lubaroff, David M.
    EXPERT REVIEW OF VACCINES, 2012, 11 (07) : 857 - 868
  • [9] Therapeutic vaccines for prostate cancer: recent advances and future directions
    Strauss, Julius
    Madan, Ravi A.
    EXPERT REVIEW OF VACCINES, 2016, 15 (07) : 907 - 914
  • [10] DNA vaccines for the treatment of prostate cancer
    Alam, Sheeba
    McNeel, Douglas G.
    EXPERT REVIEW OF VACCINES, 2010, 9 (07) : 731 - 745
12345